EP1086063A4 - Medicaments a canal potassium et leur utilisation - Google Patents

Medicaments a canal potassium et leur utilisation

Info

Publication number
EP1086063A4
EP1086063A4 EP99927330A EP99927330A EP1086063A4 EP 1086063 A4 EP1086063 A4 EP 1086063A4 EP 99927330 A EP99927330 A EP 99927330A EP 99927330 A EP99927330 A EP 99927330A EP 1086063 A4 EP1086063 A4 EP 1086063A4
Authority
EP
European Patent Office
Prior art keywords
potassium channel
novel potassium
channel drugs
drugs
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99927330A
Other languages
German (de)
English (en)
Other versions
EP1086063A1 (fr
Inventor
John R Jacobsen
Donna Eastman
John H Griffin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innoviva Inc
Original Assignee
Advanced Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Medicine Inc filed Critical Advanced Medicine Inc
Publication of EP1086063A1 publication Critical patent/EP1086063A1/fr
Publication of EP1086063A4 publication Critical patent/EP1086063A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP99927330A 1998-06-08 1999-06-07 Medicaments a canal potassium et leur utilisation Withdrawn EP1086063A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US8846598P 1998-06-08 1998-06-08
US88465P 1998-06-08
US9306898P 1998-07-16 1998-07-16
US93068P 1998-07-16
US11386498P 1998-12-24 1998-12-24
US113864P 1998-12-24
PCT/US1999/012777 WO1999064050A1 (fr) 1998-06-08 1999-06-07 Medicaments a canal potassium et leur utilisation

Publications (2)

Publication Number Publication Date
EP1086063A1 EP1086063A1 (fr) 2001-03-28
EP1086063A4 true EP1086063A4 (fr) 2001-03-28

Family

ID=27375970

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99927330A Withdrawn EP1086063A4 (fr) 1998-06-08 1999-06-07 Medicaments a canal potassium et leur utilisation

Country Status (7)

Country Link
EP (1) EP1086063A4 (fr)
JP (1) JP2002517466A (fr)
AR (1) AR015310A1 (fr)
AU (1) AU4426499A (fr)
CA (1) CA2318745A1 (fr)
SG (1) SG80037A1 (fr)
WO (1) WO1999064050A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10019067C1 (de) * 2000-04-18 2001-10-04 Lohmann Therapie Syst Lts Transdermales Therapeutisches System zur Abgabe von Dofetilid und seine Verwendung
SI1345595T1 (sl) * 2000-09-29 2007-08-31 Solvay Pharm Bv Farmacevtska oblika s podaljĺ anim sproĺ äśanjem, ki je neodvisna od ionske jakosti
JP2005506039A (ja) * 2000-12-29 2005-03-03 ネオジェネシス ファーマシューティカルズ インコーポレイテッド アフィニティ選択に基づいた疎水性タンパク質のスクリーニング
US9782488B2 (en) 2007-03-12 2017-10-10 Nektar Therapeutics Oligomer-beta blocker conjugates
KR20100135909A (ko) 2008-04-17 2010-12-27 사노피-아벤티스 심혈관성 입원 또는 사망을 예방하는데 사용하기 위한 약제의 제조에 있어서의 드로네다론의 용도
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69126124T2 (de) * 1990-09-28 1997-08-28 Neorx Corp Polymere träger zur freisetzung kovalent gebundener wirkstoffe
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GUO, WEINONG ET AL: "Evidences of antagonism between amiodarone and triiodothyronine on the K+ channel activities of cultured rat cardiomyocytes", J. MOL. CELL. CARDIOL. (1997), 29(2), 617-627, XP000922930 *
See also references of WO9964050A1 *

Also Published As

Publication number Publication date
WO1999064050A1 (fr) 1999-12-16
AR015310A1 (es) 2001-04-18
EP1086063A1 (fr) 2001-03-28
JP2002517466A (ja) 2002-06-18
CA2318745A1 (fr) 1999-12-16
SG80037A1 (en) 2001-04-17
WO1999064050A8 (fr) 2000-02-24
WO1999064050A9 (fr) 2000-04-20
AU4426499A (en) 1999-12-30

Similar Documents

Publication Publication Date Title
IL128869A0 (en) Pyrozolopyrimidines and pyrazolotriazines
HUP0101155A3 (en) Imidazonaphthyridines, pharmaceutical compositions thereof and intermediates
IL183948A (en) Peg-urate oxidase conjugates and use thereof
ZA200101933B (en) Novel composition and use
AU133942S (en) Channel member
EP1145714A4 (fr) Medicaments
EP1056765A4 (fr) Genes humains du canal potassique
ZA9811591B (en) Potassium channel openers
AU5319999A (en) Novel potassium channel molecules and uses therefor
EP1086063A4 (fr) Medicaments a canal potassium et leur utilisation
AUPO679297A0 (en) Rheology modification and modifiers
AU4629399A (en) Substituted piperazones and their therapeutic uses
CZ20011764A3 (cs) Činidla interagující s draslíkovým kanálem a jejich pouľití
AU2227999A (en) Human ependymin
EP0998578A4 (fr) Sel-10 et utilisations de sel-10
GB0005716D0 (en) Rolling member
SG80038A1 (en) Novel calcium channel drugs and uses
AU7447798A (en) Bi-directional channel analysis
GB2341533B (en) Jewellery and construction thereof
AU2202100A (en) Human brainiac-5
AU3835499A (en) Potassium channel subunit
GB9826830D0 (en) Potassium channel activators and their use
EP1066051A4 (fr) Scielline et utilisations de celle-ci
GB9817943D0 (en) Genostics and drugs
SI1040097T1 (en) Potassium channel openers

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000616

A4 Supplementary search report drawn up and despatched

Effective date: 20001005

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20010521

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20011201